Mostrar el registro sencillo del ítem

dc.contributor.authorRequena, S.
dc.contributor.authorLozano, A. B.
dc.contributor.authorCaballero, Estrella
dc.contributor.authorGarcía, F.
dc.contributor.authorNieto, M. C.
dc.contributor.authorTellez, R.
dc.contributor.author...et al.
dc.contributor.authorSoriano, Vicente (1)
dc.date2019-05
dc.date.accessioned2019-10-09T06:58:54Z
dc.date.available2019-10-09T06:58:54Z
dc.identifier.issn1460-2091
dc.identifier.urihttps://reunir.unir.net/handle/123456789/9409
dc.description.abstractBackground: HIV-2 is a neglected virus despite estimates of 1-2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. Methods: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with integrase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modalities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. Results: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126 cells/mm(3), respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). Conclusions: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individuals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.es_ES
dc.language.isoenges_ES
dc.publisherJournal of Antimicrobial Chemotherapyes_ES
dc.relation.ispartofseries;vol. 74, nº 5
dc.relation.urihttps://academic.oup.com/jac/article-abstract/74/5/1357/5315652?redirectedFrom=fulltextes_ES
dc.rightsrestrictedAccesses_ES
dc.subjectJCRes_ES
dc.subjectScopuses_ES
dc.titleClinical experience with integrase inhibitors in HIV-2-infected individuals in Spaines_ES
dc.typeArticulo Revista Indexadaes_ES
reunir.tag~ARIes_ES
dc.identifier.doihttps://doi.org/10.1093/jac/dkz007


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem